Conduit Pharmaceuticals Inc. - Asset Resilience Ratio
Conduit Pharmaceuticals Inc. (CDT) has an Asset Resilience Ratio of 11.58% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Conduit Pharmaceuticals Inc.'s working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (None–None)
This chart shows how Conduit Pharmaceuticals Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Conduit Pharmaceuticals Inc. asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Conduit Pharmaceuticals Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Conduit Pharmaceuticals Inc. to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $990.00K | 11.58% |
| Total Liquid Assets | $990.00K | 11.58% |
Asset Resilience Insights
- Moderate Liquidity: Conduit Pharmaceuticals Inc. has 11.58% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Conduit Pharmaceuticals Inc. Industry Peers by Asset Resilience Ratio
Compare Conduit Pharmaceuticals Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Conduit Pharmaceuticals Inc. (None–None)
The table below shows the annual Asset Resilience Ratio data for Conduit Pharmaceuticals Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About Conduit Pharmaceuticals Inc.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the tre… Read more